HIV/AIDS Clinical Care: Drug Watch

Crofelemer Is Approved for Noninfectious Diarrhea in HIV-Infected Patients

• HIV/AIDS Clinical Care
• Drug Watch
• Free Article

For certain patients, this botanical drug may provide a welcome new option.

• By Paul E. Sax, MD
• January 7, 2013

FDA Approves Quad for Initial HIV Treatment

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

Coformulated tenofovir/FTC/elvitegravir/cobicistat is now the third fixed-dose, once-daily antiretroviral regimen approved for treatment-naive HIV-infected patients.

• By Keith Henry, MD
• September 10, 2012

Tenofovir/FTC Approved for PrEP . . .

• HIV/AIDS Clinical Care
• Drug Watch
• Free Article

. . . but issues remain regarding implementation.

• By Paul E. Sax, MD
• July 23, 2012

Boceprevir Interacts with Boosted HIV Protease Inhibitors

• HIV/AIDS Clinical Care
• Drug Watch
• Free Article

The interaction could reduce the effectiveness of both drugs.

• By Paul E. Sax, MD
• February 13, 2012

Should Efavirenz Be Dosed Higher When Coadministered with Rifampin?

• HIV/AIDS Clinical Care
• Drug Watch
• Free Article

The FDA recommends a dosage increase in patients weighing 50 kg, but data on the interaction between these drugs are inconsistent.

• By Tanuja N. Gengiah, M Clin Pharm, MS (Epi), and Salim S. Abdool Karim, MD, PhD
• February 6, 2012

Tenofovir/FTC/Rilpivirine: A New One-Pill, Once-Daily Option for HIV Treatment

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

The fixed-dose combination was just approved by the FDA for use in treatment-naive HIV-infected individuals.

• By Paul E. Sax, MD
• August 15, 2011

Rilpivirine

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

On May 20, 2011, the FDA approved rilpivirine (Edurant), a second-generation nonnucleoside reverse transcriptase inhibitor dosed as a single pill daily, for use in treatment-naive . . .

• By Abigail Zuger, MD
• May 27, 2011

Once-Daily Nevirapine Approved by the FDA

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

A once-daily, 400-mg extended-release tablet is now available.

• By Keith Henry, MD
• April 11, 2011

New Formulation of Etravirine; Label Changes for Darunavir and d4T

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

Etravirine is now available in a 200-mg tablet, darunavir is approved for once-daily dosing in some treatment-experienced patients, and the d4T label no longer calls for dose reduction to prevent toxicity.

• By Paul E. Sax, MD
• January 10, 2011

Tesamorelin Approved for the Treatment of HIV-Related Visceral Adiposity

• HIV/AIDS Clinical Care
• Drug Watch
• Subscription Required

The drug's approval is welcome but raises a host of questions.

• By Paul E. Sax, MD
• November 22, 2010